NANOVIRICIDES, INC.
Close on Oct 19, 2026
- Market cap
- $28.93M
- P/E (TTM)
- –
- Dividend yield
- –
About Nanoviricides
Pharmaceutical Preparations, SIC 2834
NanoViricides is a clinical-stage biopharmaceutical company that develops antiviral therapies using nanomedicine technology. The company designs host-mimetic, direct-acting nanomachines that dismantle target viruses by binding to conserved cellular attachment receptors. Its primary drug candidate, NV-387, is an oral formulation evaluated for treating viral diseases such as COVID-19, mpox, and Ebola. Other development programs include NV-HHV-1 for herpesviruses and NV-HIV-1 for human immunodeficiency virus. NanoViricides is currently in the development stage and has no commercial products, active customers, or operational revenue.
The company conducts development, chemical synthesis, formulation, and analytical testing at its own manufacturing and laboratory facility in Shelton, Connecticut, which also serves as its corporate headquarters. Its clinical trials and collaborative research activities involve partner organizations and trial locations in India and the Democratic Republic of the Congo.
Summary of the business section of Nanoviricides's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NANOVIRICIDES, INC.
- Founded
- 2005
- Headquarters
- Shelton, CT
- Address
- 1 Controls Drive 06484
- Phone
- (203) 668-5580
- Website
- nanoviricides.com
- Employees
- 7, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- June 30
- Auditor
- EISNERAMPER LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- NNVC
- Exchange
- NYSE
- IPO date
- Oct 26, 2005
- Shares outstanding
- 26M, Sep 28, 2026
- Public float
- $23.69M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-20 reverse, Sep 24, 2019; 1-for-20 reverse, Sep 24, 2019; 1-for-3.5 reverse, Sep 10, 2013; 1-for-3.5 reverse, Sep 9, 2013
- SEC CIK
- 1379006
- CUSIP
- 630087302
- ISIN
- US6300873022
- LEI
- 5493003CK9Y2H0OORR73
- EIN
- 76-0674577
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Nanoviricides's leadership is listed in its proxy statement, last filed Oct 8, 2026.
Employees
Headcount reported in annual reports
“As of June 30, 2026, the Company had approximately seven full-time employees.”
Corporate history
Events identified from SEC filings